AEON Biopharma
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Park Plz Ste 1750, Irvine, California,...Phone Number
(949) 354-6499Website
www.aeonbiopharma.comRevenue
-Stock Symbol
AEONIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is based in Newport Beach, California.Explore more
AEON Biopharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AEON Biopharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AEON Biopharma has new funding data
Click to see if AEON Biopharma had a recent Job posting/layoffs
Product Launch: Get notified when AEON Biopharma launches new products
Check if AEON Biopharma has recently received funding, and reach out quickly before it becomes old news!
AEON Biopharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on AEON Biopharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at AEON Biopharma
Check out if AEON Biopharma is spiking on competitors!
Recommended Actions
Find VP level buyers at AEON Biopharma
Find more new buyers
Compare Similar Companies to AEON Biopharma
Compare insights from companies similar to AEON Biopharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AEON Biopharma
1-10
Public
$40M
2019
AW
Alexander WilsonExecutive Vice President & Chief Legal Officer & Corporate Secretary
Company Profile Activity
Activity Insights
AEON Biopharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AEON Biopharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AEON Biopharma.
AEON Biopharma financials insights
Gather financial insights about AEON Biopharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Unspecified
$20M
2025
Share Placement
$20M
AEON Biopharma Tech Stack
A closer look at the technologies used by AEON Biopharma
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
AEON Biopharma is developing AVP-450, a 900 kilodalton botulinum toxin biosimilar to Botox, with global approvals in India and Mexico, prior FDA approval in aesthetics, and 35 international approvals. The company aims to match Botox's full range of therapeutic indications at launch.
Product Development, Research & Development, Pharmaceuticals
Event
AEON Biopharma announced that Robert Bancroft, President and CEO, will present at the Aegis Annual Virtual Conference 2025.
Events
Project
AEON Biopharma is executing a comparative analytical assessment of AVP-450 and targeting a biosimilar process development (BPD) Type 2a meeting with FDA in the second half of this year to determine the next phase of development.
Research & Development, Pharmaceuticals
Project
Business Intelligence, Analytics & Insights, Pharmaceuticals
AEON Biopharma News & Media
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzedAEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development programAEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced that it has received written notice from NYSE American LLC (“NYSE American”) confirming that AEON has regained compliance with NYSE American’s continued listing standards relating to stockholders’ equity.AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering $13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AEON Biopharma
Sign Up For FreeTo access detailed company insights
AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions. The company is based in Newport Beach, California.... Read More
